A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Status:
Active, not recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This post-marketing study is designed to compare the safety of baricitinib versus tumor
necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when
given to participants with rheumatoid arthritis.